STOCK TITAN

[Form 4] COLGATE PALMOLIVE CO Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

John P. Bilbrey, a director of Colgate-Palmolive Company (CL), reported an acquisition on 10/01/2025 of 289 shares of the issuer's common stock at a price of $82.13 per share. Following the transaction, Mr. Bilbrey directly beneficially owns 36,658 shares and indirectly owns 4,719 shares through a trust. The filing states the reason for the acquisition: a portion of his annual cash retainer was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors, resulting in the issuance of common stock.

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025. No derivative transactions, dispositions, or other changes are disclosed in this Form 4.

John P. Bilbrey, membro del consiglio di Colgate-Palmolive Company (CL), ha riportato un acquisizione il 01/10/2025 di 289 azioni ordinarie dell’emittente al prezzo di $82.13 per azione. Dopo la transazione, il Signor Bilbrey possiede direttamente 36,658 azioni e indirettamente 4,719 azioni tramite una fiducia. La documentazione indica la ragione dell’acquisizione: una parte della sua retribuzione annuale in contanti è stata differita in un conto unità azionarie ai sensi del piano di compensazione differita per i direttori non dipendenti dell’azienda, comportando l’emissione di azioni ordinarie.

Il Modulo 4 è stato firmato da un procuratore in rappresentanza della persona che segnala il 03/10/2025. In questo Modulo 4 non sono indicate transazioni derivate, disposition o altri cambiamenti.

John P. Bilbrey, director de Colgate-Palmolive Company (CL), informó de una adquisición el 10/01/2025 de 289 acciones de las acciones comunes del emisor a un precio de $82.13 por acción. Después de la operación, el Sr. Bilbrey posee directamente 36,658 acciones y posee indirectamente 4,719 acciones a través de un fideicomiso. El expediente indica la razón de la adquisición: una parte de su remuneración en efectivo anual se diferió a una cuenta de unidades de acciones bajo el Plan de Compensación Diferida para Directores No Empleados de la empresa, lo que dio lugar a la emisión de acciones comunes.

El Formulario 4 fue firmado por un apoderado en nombre de la persona reportante el 03/10/2025. No se divulgan transacciones derivadas, disposiciones u otros cambios en este Formulario 4.

John P. BilbreyColgate-Palmolive Company (CL)의 이사로서 2025년 10월 1일에 발행인의 보통주 289주를 주당 $82.13의 가격으로 인수했다고 보고했습니다. 거래 이후 Bilbrey 씨는 직접 보유하는 주식이 36,658주이고, 신탁을 통해 간접 보유분이 4,719주입니다. 신고서는 취득 사유를 이유로 밝히고 있습니다: 연간 현금 수당의 일부가 회사의 비상근 이사 보상 계획에 따라 주식단위 계좌로 이연되어 일반 주식이 발행되었습니다.

Form 4는 보고자 대리인에 의해 2025년 10월 3일에 서명되었습니다. 이 Form 4에는 파생 거래, 처분 또는 기타 변경 내용은 공개되지 않았습니다.

John P. Bilbrey, administrateur de Colgate-Palmolive Company (CL), a signalé une acquisition le 01/10/2025 de 289 actions ordinaires de l’émetteur à un prix de $82.13 par action. Suite à l’opération, M. Bilbrey détient directement 36,658 actions et indirectement 4,719 actions par l’intermédiaire d’un trust. Le dossier indique la raison de l’acquisition : une partie de sa rémunération annuelle en espèces a été différée dans un compte d’unités d’actions dans le cadre du plan de rémunération différée pour les administrateurs non salariés de l’entreprise, entraînant l’émission d’actions ordinaires.

Le Formulaire 4 a été signé par un mandataire au nom de la personne déclarant le 03/10/2025. Aucune transaction dérivée, disposition ou autre changement n’est divulgué dans ce Formulaire 4.

John P. Bilbrey, ein Vorstandsmitglied der Colgate-Palmolive Company (CL), meldete einen Erwerb am 01.10.2025 von 289 Aktien der Stammaktie des Emittenten zu einem Preis von $82.13 pro Aktie. Nach der Transaktion besitzt Herr Bilbrey direkt 36.658 Aktien und besitzt indirekt 4.719 Aktien durch einen Trust. Die Einreichung gibt die Gründe für den Erwerb an: Ein Teil seiner jährlichen Barvergütung wurde in ein Aktien-Einheitenkonto gemäß dem Deferred Compensation Plan für nicht angestellte Direktoren des Unternehmens verschoben, was zur Ausgabe von Stammaktien führte.

Das Formular 4 wurde am 03.10.2025 von einem Bevollmächtigten im Auftrag der meldenden Person unterzeichnet. In diesem Formular 4 werden keine derivativen Transaktionen, Veräußerungen oder sonstigen Änderungen offengelegt.

جون بيلبري، عضو مجلس إدارة شركـة كولغيت-بالموف (CL)، قد أبلغ عن استحواذ في 10/01/2025 على 289 سهماً من أسهم الشركة العادية بسعر $82.13 للسهم الواحد. بعد الصفقة، يمتلك السيد بيلبري مباشرةً 36,658 سهماً وبشكل غير مباشر 4,719 سهماً من خلال صندوق ائتماني. يذكر الملف السبب وراء الاستحواذ: تم تأجيل جزء من مكافأته النقدية السنوية إلى حساب وحدات الأسهم بموجب خطـة التعويض المؤجل لمديري الشركة غير الموظفين، مما أدى إلى إصدار أسهم عادية.

تم توقيع النموذج 4 من قبل وكيل نيابة عن الشخص المبلغ في 03/10/2025. لا تُكشف في هذا النموذج 4 عن معاملات مشتقة أو تصرفات أو تغييرات أخرى.

John P. BilbreyColgate-Palmolive Company (CL) 的董事,报告在 2025/10/01 以每股 $82.13 的价格收购发行人普通股 289 股。交易后,Bilbrey 先生直接持有 36,658 股,透过信托间接持有 4,719 股。 filing 指出此次收购的 原因:其年度现金酬金的一部分被递延到公司为非雇员董事设立的 Deferred Compensation Plan 的股票单位账户,导致发行普通股。

Form 4 由代表申报人的代理人在 2025/10/03 签署。本 Form 4 未披露任何衍生交易、处置或其他变动。

Positive
  • None.
Negative
  • None.

John P. Bilbrey, membro del consiglio di Colgate-Palmolive Company (CL), ha riportato un acquisizione il 01/10/2025 di 289 azioni ordinarie dell’emittente al prezzo di $82.13 per azione. Dopo la transazione, il Signor Bilbrey possiede direttamente 36,658 azioni e indirettamente 4,719 azioni tramite una fiducia. La documentazione indica la ragione dell’acquisizione: una parte della sua retribuzione annuale in contanti è stata differita in un conto unità azionarie ai sensi del piano di compensazione differita per i direttori non dipendenti dell’azienda, comportando l’emissione di azioni ordinarie.

Il Modulo 4 è stato firmato da un procuratore in rappresentanza della persona che segnala il 03/10/2025. In questo Modulo 4 non sono indicate transazioni derivate, disposition o altri cambiamenti.

John P. Bilbrey, director de Colgate-Palmolive Company (CL), informó de una adquisición el 10/01/2025 de 289 acciones de las acciones comunes del emisor a un precio de $82.13 por acción. Después de la operación, el Sr. Bilbrey posee directamente 36,658 acciones y posee indirectamente 4,719 acciones a través de un fideicomiso. El expediente indica la razón de la adquisición: una parte de su remuneración en efectivo anual se diferió a una cuenta de unidades de acciones bajo el Plan de Compensación Diferida para Directores No Empleados de la empresa, lo que dio lugar a la emisión de acciones comunes.

El Formulario 4 fue firmado por un apoderado en nombre de la persona reportante el 03/10/2025. No se divulgan transacciones derivadas, disposiciones u otros cambios en este Formulario 4.

John P. BilbreyColgate-Palmolive Company (CL)의 이사로서 2025년 10월 1일에 발행인의 보통주 289주를 주당 $82.13의 가격으로 인수했다고 보고했습니다. 거래 이후 Bilbrey 씨는 직접 보유하는 주식이 36,658주이고, 신탁을 통해 간접 보유분이 4,719주입니다. 신고서는 취득 사유를 이유로 밝히고 있습니다: 연간 현금 수당의 일부가 회사의 비상근 이사 보상 계획에 따라 주식단위 계좌로 이연되어 일반 주식이 발행되었습니다.

Form 4는 보고자 대리인에 의해 2025년 10월 3일에 서명되었습니다. 이 Form 4에는 파생 거래, 처분 또는 기타 변경 내용은 공개되지 않았습니다.

John P. Bilbrey, administrateur de Colgate-Palmolive Company (CL), a signalé une acquisition le 01/10/2025 de 289 actions ordinaires de l’émetteur à un prix de $82.13 par action. Suite à l’opération, M. Bilbrey détient directement 36,658 actions et indirectement 4,719 actions par l’intermédiaire d’un trust. Le dossier indique la raison de l’acquisition : une partie de sa rémunération annuelle en espèces a été différée dans un compte d’unités d’actions dans le cadre du plan de rémunération différée pour les administrateurs non salariés de l’entreprise, entraînant l’émission d’actions ordinaires.

Le Formulaire 4 a été signé par un mandataire au nom de la personne déclarant le 03/10/2025. Aucune transaction dérivée, disposition ou autre changement n’est divulgué dans ce Formulaire 4.

John P. Bilbrey, ein Vorstandsmitglied der Colgate-Palmolive Company (CL), meldete einen Erwerb am 01.10.2025 von 289 Aktien der Stammaktie des Emittenten zu einem Preis von $82.13 pro Aktie. Nach der Transaktion besitzt Herr Bilbrey direkt 36.658 Aktien und besitzt indirekt 4.719 Aktien durch einen Trust. Die Einreichung gibt die Gründe für den Erwerb an: Ein Teil seiner jährlichen Barvergütung wurde in ein Aktien-Einheitenkonto gemäß dem Deferred Compensation Plan für nicht angestellte Direktoren des Unternehmens verschoben, was zur Ausgabe von Stammaktien führte.

Das Formular 4 wurde am 03.10.2025 von einem Bevollmächtigten im Auftrag der meldenden Person unterzeichnet. In diesem Formular 4 werden keine derivativen Transaktionen, Veräußerungen oder sonstigen Änderungen offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
BILBREY JOHN P

(Last) (First) (Middle)
C/O COLGATE-PALMOLIVE COMPANY
300 PARK AVENUE

(Street)
NEW YORK NY 10022

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A(1) 289 A $82.13 36,658 D
Common Stock 4,719 I By Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors.
/s/ Kristine Hutchinson, Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Colgate-Palmolive director John P. Bilbrey report (CL)?

He reported an acquisition of 289 common shares on 10/01/2025 at $82.13 per share.

How many Colgate-Palmolive shares does John P. Bilbrey own after the reported transaction?

He directly owns 36,658 shares and indirectly owns 4,719 shares through a trust.

Why were the shares acquired by the director?

The filing states the shares resulted from a portion of his annual cash retainer being deferred to a stock unit account under the Deferred Compensation Plan for Non-Employee Directors.

When was the Form 4 filed and who signed it?

The Form 4 lists the transaction date as 10/01/2025 and was signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.

Were there any derivative securities or dispositions reported in this Form 4 for CL?

No; the filing shows only the non-derivative acquisition of common stock and does not report derivative transactions or dispositions.
Colgate Palmolive Co

NYSE:CL

CL Rankings

CL Latest News

CL Latest SEC Filings

CL Stock Data

63.29B
806.85M
0.16%
86.07%
1.44%
Household & Personal Products
Perfumes, Cosmetics & Other Toilet Preparations
Link
United States
NEW YORK